secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0001193125-24-220529
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology appoints Michael Vasconcelles, M.D. to board and compensation committee
--------------------------------------------------------------------------------

- Appointed as Class III director with term expiring at 2026 annual meeting.
- Annual cash retainer $40,000 for board service plus $7,500 for Compensation Committee.
- Granted option to purchase 52,000 shares (3-year vest) and 17,333 shares (1-year cliff).
- Eligible for future automatic annual option grants of 26,000 shares.
- Standard indemnification agreement; no reportable transactions under Item 404.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312524220529/0001193125-24-220529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312524220529/d866748d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-220529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer